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γ-Glutamyl-dipeptides, built by condensing the distal carboxylate of L-Glu (or D-Glu) onto a series 
of differently functionalized amino acids, were prepared and used as tools for rapidly probing the 
stereo-electronic properties of iGluRs, searching for subtype-selective ligands. 
 









1. Introduction  
L-Glutamic acid (L-Glu, Figure 1) is the main excitatory 
neurotransmitter in the central nervous system (CNS), where it is 
involved in the modulation of many physiological processes such 
as learning, memory, and synaptic plasticity.1 Once released into 
the synaptic cleft, L-Glu acts through both ionotropic and 
metabotropic L-Glu receptors (iGluRs and mGluRs, respectively). 
The iGluRs are divided into three classes based on sequence 
homology and ligand selectivity: N-methyl-D-aspartic acid 
(NMDA) receptors, (RS)-2-amino-3-(3-hydroxy-5-methyl-4-
isoxazolyl)propionic acid (AMPA) receptors, and kainic acid 
(KA) receptors. These classes of receptors are further subdivided 
into subtypes.1-5 The action of L-Glu is then silenced by a specific 
reuptake transport system, the excitatory amino acid transporters 
(EAATs), which are localized both at the synaptic nerve terminals 
and at glial cells. 
Starting from the structure of the endogenous ligand L-Glu, 
selectivity for iGluRs vs mGluRs can be achieved through 
conformational constraint, locking the ligand into a folded or 
extended conformation, respectively (e.g., compound L-CCG-
IV vs L-CCG-I, Figure1).6 In contrast, when it comes to the 
design of ligands selective for a specific iGluR or, ideally, for 
an iGluR subtype, common strategies often rely on the 
increase of molecular complexity.7 This strategy aims at 
exploiting the subtle differences among iGluRs in terms of 
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stereo-electronic properties of the ligand binding domain 
(LBD) of the different receptor subunits (GluN1, GluN2A-C, 







































Figure 1. Structure of model compounds 
 
Tetrahedron 2 
For instance, GluK1 selective agonists, such as the 5-tert-butyl 
derivative of AMPA, 2-amino-3-(5-tert-butyl-3-hydroxy-4-
isoxazolyl) propionic acid (ATPA) and 5-iodowillardine (Figure 
1), are sterically hindered by the side chain of Asp690 when 
docked into the GluK2 pocket and this is relieved by the presence 
of the smaller Ser706 at the equivalent position in GluK1.7 Steric 
obstruction may also explain the reduced selectivity of ATPA for 
AMPARs. Steric occlusion partly explains also the higher 
selectivity of the agonist (2S,4R)-4-methylglutamate (SYM 2081, 
Figure 1) for kainate receptors over AMPA receptors.8 In addition, 
homologation of the amino acidic chain is a strategy often pursued 
to turn agonists into antagonists, because it prevents the closure of 
the clamshell like LBD, thus leaving the channel pore closed.9,10 
Finally, it has to be noticed that, whereas AMPA and KA receptor 
ligands, analogously to the endogenous agonist L-Glu, usually are 
characterized by an S-configuration at the α-amino acid 
stereogenic center, NMDA receptors often exhibit a preference for 
R-configured amino acids, as in the case of the prototypical agonist 
NMDA. 
On this ground, we envisaged that γ-glutamyl-dipeptides, built 
by condensing the distal carboxylate of L-Glu (or D-Glu) to a series 
of differently functionalized amino acids, could represent an easy 
strategy to synthesize ligands, featuring as ideal tools for rapidly 
probing the stereo-electronic properties of iGluRs, searching for 
subtype-selective antagonists (Figure 2). Indeed, γ-glutamyl-
dipeptides are acidic amino acids characterized by a 6-atom spacer 
connecting the proximal and the distal acidic functions and by 
different side chains useful to confer an increasing degree of 
molecular complexity to the molecules, making possible the 









































































D-Lys--D-Glu, 22  
 
Figure 2. Structure of target compounds 
 
2. Results and discussion 
2.1.  Chemistry 
L-Glu (or D-Glu) was used as the starting material for the 
synthesis of the suitably protected amino acid 23 (Scheme 1), 
obtained in good yield and high purity, following a literature 
procedure.11 On the other hand, each amino acid used in the 
coupling reaction was protected at the carboxylic function using 
thionyl chloride in MeOH, yielding the corresponding methyl ester 
in quantitative yield as a hydrochloride salt. The amino acids Lys, 
Glu and Ser were further protected at the side chain functional 
groups.12 The coupling reaction was performed exploiting the use 
of a flow chemistry reactor in combination with an immobilized 
coupling reagent (polymer supported (PS)-HOBt) and 
scavengers.13 PS-HOBt was packed into an Omnifit® glass 
column, then, after a washing/swelling step with DMF, a solution 
of the carboxylic acid 23, DIPEA and the phoshponium coupling 
reagent bromo-tris-pyrrolidino phosphonium 
hexafluorophosphate (PyBroP) in DMF was fluxed through it at 
100 μL/min (Scheme 1, step A). The column was then washed with 
DMF, leaving an activated amino ester covalently attached to the 
polymer support. The column was then connected with two 
prewashed columns of Amberlyst A-21 and Amberlyst A-15 
linked in series (Scheme 1, step B). A solution of the second amino 
acid methyl ester as hydrochloride salt in DMF was fluxed through 
the column containing A-21 to liberate the free amine, which was 
then fluxed into the column containing the activated ester, where 
the coupling took place. The exiting flow stream was finally 
directed into the column filled with A-15 to perform an in-line 























Scheme 1. In flow coupling reaction   
 
The resulting solution was then evaporated to obtain the 
protected dipeptides 24-45 in high yields (75-90%), in high 
purities (> 95%) without any aqueous work up or column 
chromatography and with a significant reduction of time 
compared to traditional batch synthesis (20 min vs 2 h). The 
final compounds 1-22 were obtained after deprotection of 
intermediates 24-45 (Scheme 2). These steps were easily 
carried out in batch, through the hydrolysis of the esters with 
1 N NaOH in MeOH and removing the Boc protecting groups 
in acidic conditions using a 30% trifluoroacetic acid solution 
in CH2Cl2 (Scheme 2). These acidic conditions allowed also 
the removal of the trityl protecting group in intermediates 29, 
30, 40 and 41. In the case of compounds 21 and 22, which 
possess the distal amino function of Lys, the acidic ion 
 3 
exchange resin Amberlite IR-120 was used to liberate the 






































































All dipeptides were preliminarily submitted to binding assays 
at native iGluRs, using rat brain synaptic membranes from male 
Sprague–Dawley rats.  
 








1 > 100 4.15.39  0.05   5.4 5.29  0.07 
2 > 100 10 5.00  0.03   40 4.42  0.10 
3 > 100 > 100 > 100 
4 > 100 15 4.81  0.02   44 4.39  0.11 
5 > 100 > 100 > 100 
6 > 100 4.0 5.40  0.04  5.8 5.27 0.10 
7 > 100 42 4.38  0.07    21 4.73 0.10  
8 8.4 5.08 ± 0.07  0.74 6.15  0.10  0.92 6.04 0.03 
9 > 100 24 4.62  0.03   9.6 5.04  0.08 
10 > 100 9.8 5.06  0.14  22 4.73  0.14 
11 > 100 > 100 > 100 
12 > 100 > 100 7.2 5.15 ± 0.05 
13 > 100 > 100 21 4.67 ± 0.03 
14 > 100 > 100 > 100 
15 > 100 > 100 ≥ 100 
16 >100 > 100 > 100 
17 > 100 > 100 6.8 5.18 ± 0.06 
18 ≥ 100 25 4.60 ± 0.03    33 4.51 ± 0.09 
19 > 100 > 100 3.3 5.48 ± 0.01 
20 > 100 > 100 85 4.07 ± 0.01 
21 > 100 > 100 72 4.14 ± 0.02 
22 > 100 > 100 > 100 
[a] Data are given as mean mean pKi  SEM of three to four 
independent experiments each conducted in triplicate. 
 
These binding data show that several compounds characterized 
by the presence of the L-Glu moiety displayed moderate affinity 
(IC50 ≤ 10 µM) for native KARs (i.e., compounds 1, 2, 6, 8 and 
10). Unfortunately, the compounds lack KAR selectivity because 
they also exhibited affinity towards NMDA receptors. Indeed, the 
highest-affinity hit 8 and the compounds 1 and 6 displayed high 
affinity also for NMDARs (Ki = 0.9, 5.4 and 5.8 µM, respectively), 
The ability of the endogenous dipeptide γ-L-Glu-L-Glu and few 
other dipeptides or tripeptides (such as glutathione) to bind with 
micromolar affinity to ionotropic glutamate receptors was 
previously observed.14 Interestingly, several derivatives within the 
D-Glu series (i.e., compounds 12, 13, 17 and 19) behaved as 
selective NMDA receptor ligands exhibiting low micromolar 
binding affinities (Ki = 7.2, 21, 6.8 and 3.3 µM, respectively) at 
these receptors. 
In parallel, since it is known that an increase in molecular 
complexity of the aspartate/glutamate skeleton may generate 
molecules that act as blockers of the EAATs,15 we have also tested 
the new derivatives 1-11 as potential inhibitors of the EAAT 
subtypes 1, 2 and 3 (EAAT1-3). In detail, the inhibition of the 
compounds at human EAAT1-3 stably expressed in HEK293 cells 
was determined in a [3H]-D-Aspartate uptake assay performed as 
previously described using L-Glu and D,L-TBOA as reference 
ligands.16 Compound 6 displayed weak inhibitory activity at all the 
three transporters at high micromolar concentrations, while the 
other derivatives proved to be inactive up to concentrations of 300 
M or 1000 M. 
 
4. Conclusion 
In the present work, we have developed an easy route to rapidly 
generate a small library of ligands able to interact, with different 
binding affinities and degrees of selectivity, with KA and NMDA 
receptors. The length of the amino acidic skeleton obtained by 
coupling the distal carboxylate of D- or L-Glu, to an α-amino acid 
seems to be appropriate to fit the iGluR binding site, whereas 
additional natural and non-natural amino acids remain to be 
investigated, in order to maximize the receptor affinity and 
possibly increase the selectivity profile. 
 
5. Experimental  
5.1 Materials and methods 
All reagents were purchased from Sigma. 1H NMR and 13C 
NMR spectra were recorded with a Varian Mercury 300 (300 
MHz) spectrometer. Chemical shifts (δ) are expressed in ppm 
downfield from tetramethylsilane, and coupling constants (J) are 
expressed in Hz. Optical rotation determinations were carried out 
using a Jasco P-1010 spectropolarimeter, coupled with a Haake 
N3-B thermostat. TLC analyses were performed on commercial 
silica gel 60 F254 aluminum sheets; spots were further evidenced 
by spraying with a dilute alkaline potassium permanganate 
solution or ninhydrin. MS analyses were performed on a Varian 
320-MS triple quadrupole mass spectrometer with ESI source. 
Microanalyses (C, H, N) of new compounds were within ±0.4% of 
theoretical values. The continuous-ﬂow peptide synthesis was 
performed using a R2+/R4 ﬂow reactor, commercially available 
from Vapourtec equipped with Omniﬁt glass column. 
5.2 Binding assays 
Affinities for native NMDA, AMPA, and KA receptors in rat 
cortical synaptosomes were determined using 2 nM 
Tetrahedron 4 
[3H]CGP39653, 5 nM [3H]AMPA, and 5 nM [3H]KA, 
respectively, with minor modifications as previously described.17 
5.3. General procedures 
5.3.1 General procedure for peptide coupling. 
0.5 g of PS-HOBt was packed (loading 1.0 mmol/g) into a glass 
column (Ø: 6.6 mm; h: 100 mm) and DMF was fluxed for 15 
minutes (flow rate: 200 µL/min). PyBroP (559 mg, 1.2 mmol) and 
DIPEA (261 µL; 1.5 mmol) were added to a 0.5 M solution of 23 
(275 mg; 1.0 mmol in 2.0 mL of DMF) and the resulting solution 
was fluxed into the flow reactor at 100 μL/min. 0.5 g of Amberlyst 
A-21 was packed into a glass column (Ø: 6.6 mm; h: 100) and 
DMF was fluxed for 10 minutes (flow rate: 200 µL/min). 0.5 g of 
Amberlyst A-15 were packed into a third glass column (Ø: 6.6 
mm; h: 100 mm) and DMF was fluxed for 10 minutes (flow rate: 
200 µL/min). The column containing A-21 was connected in series 
with the column packed with PS-HOBt and with the column 
containing A-15. A 100 psi backpressure regulator was connected. 
A 0.2 M solution of the amino acid methyl ester hydrochloride (0.5 
mmol in 2.5 mL of DMF) was injected into the reactor. The flow 
rate was set in order to obtain a residence time of 20 minutes.  
5.3.2 General procedure for dipeptide deprotection. 
1) The protected dipeptide (0.5 mmol) was dissolved in MeOH 
(1.5 mL) and 1N NaOH (1.5 mL, 1.5 mmol) was added. The 
mixture was stirred at rt for 3 h and the disappearance of the 
starting material was monitored by TLC (CH2Cl2/MeOH 9/1 + 1% 
AcOH). After evaporation of MeOH, the residue was diluted with 
distilled H2O (5 mL) and washed with CH2Cl2 (2  5 mL). After 
that, the aqueous phase was made acidic (pH = 2) with 2N aqueous 
HCl and then extracted with EtOAc (3  5 mL). The organic phase 
was dried over anhydrous Na2SO4 and, after evaporation of the 
solvent, the intermediate was obtained as a white solid. 
2) The intermediate obtained from the previous step (0.5 mmol) 
was treated with a 30% solution of TFA in CH2Cl2 (1.25 mL) at 0 
°C. The solution was stirred at rt for 2 h and the reaction was 
followed by TLC (CH2Cl2/MeOH 9/1 + 1% AcOH). The volatiles 
were removed under reduced pressure. The obtained solid was 




Yield: 80%; purple oil; Rf (cyclohexane/EtOAc 1/1): 0.41; 
[α]D20: + 11.6 (c: 1.00 in CHCl3); 1H NMR (300 MHz, CDCl3): 
1.25 (t, J = 7.0, 3H); 1.45 (s, 9H); 1.80‒2.00 (m, 1H); 2.10‒2.25 
(m, 1H); 2.30‒2.38 (m, 2H); 3.75 (s, 3H); 4.05 (dd, J = 5.5, 9.4, 
2H); 4.20 (q, J = 7.0, 2H); 4.25‒4.40 (m, 1H); 5.35 (bd, J = 7.1, 
1H); 6.70 (bd, J = 5.5, 1H); 13C NMR (75 MHz, CDCl3): 14.4, 
28.5, 29.4, 32.5, 41.5, 52.6, 53.1, 61.8, 80.3, 156.2, 170.7, 172.5, 
172.6. Anal. calcd for C15H26N2O7: C, 52.01; H, 7.57; N, 8.09; 
found: C, 52.30; H, 7.68; N, 8.17.  
5.5 (S)-Ethyl 2-(tert-butoxycarbonylamino)-5-((S)-1-methoxy-
1-oxo-3-phenylpropan-2-ylamino)-5-oxopentanoate (25) 
Yield: 76%; yellow oil; Rf (cyclohexane/EtOAc 6/4): 0.3; 
[α]D20: + 37.5 (c: 1.00 in CHCl3); 1H-NMR (300 MHz, CDCl3): 
1.25 (t, J = 7.0, 3H); 1.45 (s, 9H); 1.85‒2.00 (m, 1H); 2.10‒2.20 
(m, 1H); 2.20‒2.30 (m, 2H); 3.10 (dd, J = 6.8, 14.1, 1H); 3.15 (dd, 
J = 5.4, 14.1, 1H); 3.75 (s, 3H); 4.20 (q, J = 7.0, 2H); 4.35‒4.45 
(m, 1H); 4.80‒4.90 (m, 1H); 5.20 (bd, J = 6.9, 1H); 6.35 (bd, J = 
5.8, 1H); 7.10‒7.15 (m, 2H); 7.20‒7.30 (m, 3H); 13C-NMR (75 
MHz, CDCl3): 14.4, 28.5, 29.7, 32.6, 38.0, 52.6, 53.1, 53.8, 61.8, 
80.4, 127.3, 128.8, 129.5, 136.3, 156.2, 172.1, 172.4, 172.5. Anal. 
calcd for C22H32N2O7: C, 60.54; H, 7.39; N, 6.42; found: C, 60.21; 




Yield: 88%; yellow oil; Rf (cyclohexane/EtOAc 6/4): 0.22; 
[α]D20: ‒ 20.3 (c: 1.00 in CHCl3); 1H-NMR (300 MHz, CDCl3): 
1.25 (t, J = 7.0, 3H); 1.45 (s, 9H); 1.80‒1.90 (m, 1H); 2.10‒2.30 
(m, 3H); 3.06 (dd, J = 6.8, 14.1, 1H); 3.17 (dd, J = 5.4, 14.1, 1H); 
3.75 (s, 3H); 4.20 (q, J = 7.0, 2H); 4.35‒4.45 (m, 1H); 4.80‒4.90 
(m, 1H); 5.30 (bd, J = 6.8, 1H); 6.75 (bd, J = 5.9, 1H); 7.10‒7.20 
(m, 2H); 7.20‒7.30 (m, 3H); 13C-NMR (75 MHz, CDCl3): 14.4, 
28.5, 29.7, 32.6, 38.0, 52.6, 53.1, 53.8, 61.8, 80.4, 127.3, 128.8, 
129.5, 136.3, 156.2, 172.1, 172.4, 172.5. Anal. calcd for 
C22H32N2O7: C, 60.54; H, 7.39; N, 6.42; found: C, 60.30; H, 7.28; 
N, 6.55.  
5.7 (S)-Ethyl 2-(tert-butoxycarbonylamino)-5-((S)-1-methoxy-
4-methyl-1-oxopentan-2-ylamino)-5-oxopentanoate (27) 
Yield: 82%; yellow oil; Rf (cyclohexane/EtOAc 6/4): 0.30; 
[α]D20: + 5.5 (c: 1.10 in CHCl3); 1H-NMR (300 MHz, CDCl3): 0.94 
(d, J = 6.3, 6H); 1.25 (t, J = 7.1, 3H); 1.45 (s, 9H); 1.50‒1.70 (m, 
3H); 1.80‒1.90 (m, 1H); 2.10‒2.25 (m, 1H); 2.28‒2.36 (m, 2H); 
3.75 (s, 3H); 4.20 (q, J = 7.1, 2H); 4.20‒4.30 (m, 1H); 4.55‒4.65 
(m, 1H); 5.25 (bd, J = 7.7, 1H); 6.35 (bd, J = 6.6, 1H); 13C-NMR 
(75 MHz, CDCl3): 14.4, 22.1, 23.1, 25.1, 28.5, 29.3, 32.6, 41.7, 
51.0, 52.5, 53.2, 61.8, 80.3, 156.1, 171.9, 172.5, 173.8. Anal. calcd 
for C19H34N2O7: C, 56.70; H, 8.51; N, 6.96; found: C, 57.01; H, 
8.65; N, 7.17.  
5.8 (S)-Ethyl 2-(tert-butoxycarbonylamino)-5-((R)-1-methoxy-
4-methyl-1-oxopentan-2-ylamino)-5-oxopentanoate (28) 
Yield: 75%; yellow oil; Rf (cyclohexane/EtOAc 6/4): 0.20; 
[α]D20: + 12.7 (c: 1.55 in CHCl3); 1H-NMR (300 MHz, CDCl3): 
0.94 (d, J = 6.0, 6H); 1.25 (t, J = 7.0, 3H); 1.45 (s, 9H); 1.50‒1.70 
(m, 3H); 1.80‒1.90 (m, 1H); 2.10‒2.25 (m, 1H); 2.28‒2.36 (m, 
2H); 3.75 (s, 3H); 4.20 (q, J = 7.0, 2H); 4.35‒4.45 (m, 1H); 4.50‒
4.60 (m, 1H); 5.32 (bd, J = 7.1, 1H); 6.90 (bd, J = 6.8, 1H); 13C-
NMR (75 MHz, CDCl3): 14.4, 22.1, 23.1, 25.1, 28.5, 29.9, 32.7, 
41.4, 51.3, 52.5, 53.1, 61.8, 80.5, 156.3, 172.3, 172.6, 173.8. Anal. 
calcd for C19H34N2O7: C, 56.70; H, 8.51; N, 6.96; found: C, 56.96; 
H, 8.67; N, 7.12.  
5.9 (S)-Ethyl 2-(tert-butoxycarbonylamino)-5-((S)-1-methoxy-
1-oxo-3-(trityloxy)propan-2-ylamino)-5-oxopentanoate (29) 
Yield: 75%; Solid state: pale yellow oil; Rf 
(cyclohexane/EtOAc 7/3): 0.21; [α]D20: ‒ 21.0 (c: 1.00 in CHCl3); 
1H-NMR (300 MHz, CDCl3): 1.25 (t, J = 7.0, 3H); 1.45 (s, 9H); 
1.85‒2.00 (m, 1H); 2.10‒2.20 (m, 1H); 2.30 (m, 2H); 3.35 (dd, J 
= 3.3, 9.4, 1H); 3.60 (dd, J = 3.3, 9.4, 1H); 3.75 (s, 3H); 4.15 (q, J 
= 7.0, 2H); 4.20‒4.30 (m, 1H); 4.70 (ddd, J = 3.3, 3.3, 8.0, 1H); 
5.24 (bd, J = 8.0, 1H); 6.55 (bd, J = 8.3, 1H); 7.20‒7.40 (m, 15H); 
13C-NMR (75 MHz, CDCl3): 14.4, 28.5, 28.9, 32.6, 52.6, 52.9, 
60.6, 61.7, 63.8, 80.7, 86.9, 127.5, 128.1, 128.7, 143.6, 155.8, 
171.2, 171.8, 172.5. Anal. calcd for C35H42N2O8: C, 67.94; H, 6.84; 





Yield: 77%; Solid state: yellow oil; Rf (cyclohexane/EtOAc 
1/1): 0.63; [α]D20: ‒ 1.0 (c: 1.00 in CHCl3); 1H-NMR (300 MHz, 
CDCl3): 1.25 (t, J = 7.0, 3H); 1.45 (s, 9H); 1.80‒2.00 (m, 1H); 
2.10‒2.40 (m, 3H); 3.35 (dd, J = 3.2, 9.4, 1H); 3.60 (dd, J = 3.2, 
9.4, 1H); 3.75 (s, 3H); 4.20 (q, J = 7.0, 2H); 4.35‒4.45 (m, 1H); 
4.72 (ddd, J = 3.2, 3.2, 7.9, 1H); 5.35 (bd, J = 7.9, 1H); 6.86 (bd, 
J = 7.9, 1H); 7.20‒7.40 (m, 15H); 13C-NMR (75 MHz, CDCl3): 
14.4, 28.5, 29.0, 32.5, 52.9, 53.1, 59.4, 61.8, 63.1, 80.6, 86.9, 
127.5, 128.1, 128.9, 143.6, 156.1, 171.2, 171.2, 172.5. Anal. calcd 
for C35H42N2O8: C, 67.94; H, 6.84; N, 4.53; found: C, 68.24; H, 
7.00; N, 4.40. 
5.11 (S)-Dimethyl 2-((S)-4-(tert-butoxycarbonylamino)-5-
ethoxy-5-oxopentanamido)pentanedioate (31) 
Yield: 83%; crystallized from diisopropyl ether as white 
crystals; mp: 95-97 °C; Rf (cyclohexane/EtOAc 4/6): 0.37; [α]D20: 
+ 21.4 (c: 1.00 in CHCl3); 
1H-NMR (300 MHz, CDCl3): 1.25 (t, J 
= 7.1, 3H); 1.45 (s, 9H); 1.90‒2.10 (m, 2H); 2.15‒2.25 (m, 2H); 
2.30‒2.40 (m, 2H); 2.40‒2.50 (m, 2H); 3.65 (s, 3H); 3.75 (s, 3H); 
4.20 (q, J = 7.1, 2H); 4.20‒4.30 (m, 1H); 4.60 (ddd, J = 5.0, 7.6, 
7.6, 1H); 5.25 (bd, J = 7.6, 1H); 6.60 (bd, J = 7.6, 1H). Anal. calcd 
for C19H32N2O9 C, 52.77; H, 7.46; N, 6.48; found: C, 52.96; H, 
7.70; N, 6.25. 
5.12 (R)-Dimethyl 2-((S)-4-(tert-butoxycarbonylamino)-5-
ethoxy-5-oxopentanamido)pentanedioate (32) 
Yield: 73%; crystallized from diisopropyl ether as white 
crystals; mp: 75-77 °C; Rf (cyclohexane/EtOAc 1/1): 0.19; [α]D20: 
‒ 6.5 (c: 1.00 in CHCl3); 1H-NMR (300 MHz, CDCl3): 1.25 (t, J = 
7.0, 3H); 1.45 (s, 9H); 1.85‒2.00 (m, 1H); 2.00‒2.10 (m, 1H); 
2.15‒2.25 (m, 2H); 2.30‒2.40 (m, 2H); 2.40‒2.50 (m, 2H); 3.65 
(s, 3H); 3.75 (s, 3H); 4.20 (q, J = 7.0, 2H); 4.35‒4.45 (m, 1H); 4.60 
(ddd, J = 5.0, 7.6, 7.6, 1H); 5.31 (bd, J = 7.6, 1H); 6.75 (bd, J = 
7.6, 1H). Anal. calcd for C19H32N2O9 C, 52.77; H, 7.46; N, 6.48; 




Yield: 79%; yellow oil; Rf (cyclohexane/EtOAc 1/1): 0.33; 
[α]D20: + 8.0 (c: 0.50 in CHCl3); 1H-NMR (300 MHz, CDCl3): 1.25 
(t, J = 7.0, 3H); 1.45 (s, 18H); 1.30‒1.50 (m, 1H); 1.65‒1.95 (m, 
6H); 2.10‒2.25 (m, 1H); 2.30‒2.40 (m, 2H); 3.05‒3.15 (m, 2H); 
3.75 (s, 3H); 4.20 (q, J = 7.0, 2H); 4.20‒4.30 (m, 1H); 4.55 (ddd, 
J = 5.0, 7.7, 7.7, 1H); 4.65 (bs., 1 H); 5.25 (bd, J = 7.7, 1H); 6.50 
(bd, J = 7.7, 1H); 13C-NMR (75 MHz, CDCl3): 14.4, 22.7, 28.5, 
28.6, 29.6, 29.8, 31.9, 32.6, 40.3, 52.4, 52.5, 53.1, 61.8, 79.3, 80.4, 
156.2, 156.3, 172.3, 172.6, 173.1. Anal. calcd for C24H43N3O9 C, 




Yield: 87%; crystallized from diisopropyl ether as white 
crystals; mp: 75 °C; Rf (cyclohexane/EtOAc 1/1): 0.40; [α]D20: + 
5.3 (c: 0.50 in CHCl3); 
1H-NMR (300 MHz, CDCl3): 1.25 (t, J = 
7.1, 3H); 1.45 (s, 18H); 1.35‒1.50 (m, 1H); 1.65‒1.95 (m, 6H); 
2.10‒2.25 (m, 1H); 2.30‒2.40 (m, 2H); 3.05‒3.15 (m, 2H); 3.75 
(s, 3H); 4.20 (q, J = 7.1, 2H); 4.35‒4.45 (m, 1H); 4.55 (ddd, J = 
5.0, 7.4, 7.4, 1H); 4.65 (bs., 1 H); 5.30 (bd., J = 6.6, 1H); 6.90 (bd., 
J = 6.6, 1H); 13C-NMR (75 MHz, CDCl3): 14.4, 22.7, 28.5, 28.6, 
29.5, 29.8, 31.9, 32.6, 40.3, 52.4, 52.5, 53.1, 61.8, 79.3, 80.4, 
156.2, 156.3, 172.3, 172.5, 173.1. Anal. calcd for C24H43N3O9 C, 
55.69; H, 8.37; N, 8.12; found: C, 55.99; H, 8.50; N, 7.95. 
5.15 (R)-Ethyl 2-(tert-butoxycarbonylamino)-5-(2-methoxy-2-
oxoethylamino)-5-oxopentanoate (35) 
[α]D20: ‒ 11.3 (c: 1.00 in CHCl3). Anal. calcd for C15H26N2O7: 




[α]D20: + 19.7 (c: 1.00 in CHCl3). Anal. calcd for C22H32N2O7: 




[α]D20: ‒ 37.0 (c: 1.00 in CHCl3). Anal. calcd for C22H32N2O7: 




[α]D20: ‒ 13.1 (c: 1.10 in CHCl3). Anal. calcd for C19H34N2O7: 




[α]D20: ‒ 5.3 (c: 1.00 in CHCl3). Anal. calcd for C19H34N2O7: C, 




[α]D20: + 1.3 (c: 1.00 in CHCl3). Anal. calcd for C35H42N2O8: C, 




[α]D20: + 20.6 (c: 1.00 in CHCl3). Anal. calcd for C35H42N2O8: 
C, 67.94; H, 6.84; N, 4.53; found: C, 68.20; H, 6.98; N, 4.32. 
5.22 (S)-Dimethyl 2-((R)-4-(tert-butoxycarbonylamino)-5-
ethoxy-5-oxopentanamido)pentanedioate (42) 
[α]D20: + 6.9 (c: 1.00 in CHCl3). Anal. calcd for C19H32N2O9 C, 
52.77; H, 7.46; N, 6.48; found: C, 53.00; H, 7.70; N, 6.32. 
5.23 (R)-Dimethyl 2-((R)-4-(tert-butoxycarbonylamino)-5-
ethoxy-5-oxopentanamido)pentanedioate (43) 
[α]D20: – 21.0 (c: 0.95 in CHCl3). Anal. calcd for C19H32N2O9 C, 





[α]D20: – 5.0 (c: 0.50 in CHCl3). Anal. calcd for C24H43N3O9 C, 




[α]D20: ‒ 8.0 (c: 0.50 in CHCl3). Anal. calcd for C24H43N3O9 C, 
55.69; H, 8.37; N, 8.12; found: C, 55.90; H, 8.52; N, 7.95. 
5.26 (S)-2-Amino-5-(carboxymethylamino)-5-oxopentanoic 
acid (1) 
Yield: 31%; Rf (n-butanol/H2O/AcOH 4:2:1): 0.18; mp: dec. T 
> 159 °C; [α]D20: + 10.0 (c: 0.30 in H2O); lit.18 [α]D20: + 11.1 (c: 
1.00 in H2O); 
1H-NMR (300 MHz, D2O): 2.00‒2.08 (m, 2H); 2.35 
(ddd, J = 1.4, 8.5, 8.5, 2H); 3.70 (dd, J = 6.3, 6.3, 1H); 3.80 (s, 
2H); 13C-NMR (75 MHz, D2O): 26.1, 31.2, 41.5, 53.6, 173.3, 
174.0, 175.2; [M+H]+: 205.0. Anal. calcd for C7H12N2O5 C, 41.18; 
H, 5.92; N, 13.72; found: C, 41.00; H, 5.80; N, 13.89. 
5.27 (S)-2-Amino-5-((S)-1-carboxy-2-phenylethylamino)-5-
oxopentanoic acid (2) 
Yield: 80%; Rf  (n-butanol/H2O/AcOH 4:2:1): 0.49; [α]D20: + 
18.2 (c: 0.25 in H2O); mp: T > 186-189 °C; 
1H-NMR (300 MHz, 
D2O): 1.80‒1.90 (m, 2H); 2.25 (m, 2H); 2.85 (dd, J = 9.3, 14.0, 
1H); 3.10 (dd, J = 5.3, 14.0, 1H); 3.60 (dd, J = 6.5, 6.5, 1H); 4.55 
(dd, J = 5.3, 9.3 1H); 7.10‒7.30 (m, 5H); 13C-NMR (75 MHz, 
D2O): 26.1, 31.3, 36.8, 53.2, 54.3, 127.3, 128.8, 129.3, 136.8, 
172.7, 174.2, 175.3; [M+H]+: 295.0. Anal. calcd for C14H18N2O5 
C, 57.13; H, 6.16; N, 9.52; found: C, 56.90; H, 6.28; N, 9.40. 
5.28 (S)-2-Amino-5-((R)-1-carboxy-2-phenylethylamino)-5-
oxopentanoic acid (3) 
Yield: 89%; Rf (CH2Cl2/MeOH 9:1 + 1% AcOH): 0.62; [α]D20: 
+ 3.7 (c: 0.30 in H2O); mp: 150 °C; 
1H-NMR (300 MHz, D2O): 
1.80‒2.00 (m, 2H); 2.28 (ddd, J = 3.0, 8.2, 8.2, 2H); 2.82 (dd, J = 
9.7, 14.1, 1H); 3.12 (dd, J = 5.3, 14.1, 1H); 3.60 (dd, J = 3.0, 6.5, 
1H); 4.55 (dd, J = 5.3, 9.7, 1H); 7.10‒7.25 (m, 5H); 13C-NMR (75 
MHz, D2O): 25.7, 30.4, 36.8, 52.2, 54.0, 127.2, 128.8, 129.4, 
136.8, 171.8, 174.0, 175.1; [M+H]+: 295.0. Anal. calcd for 
C14H18N2O5 C, 57.13; H, 6.16; N, 9.52; found: C, 57.32; H, 5.98; 
N, 9.78. 
5.29 (S)-2-Amino-5-((S)-1-carboxy-3-methylbutylamino)-5-
oxopentanoic acid (4) 
Yield: 100%; Rf (n-butanol/H2O/AcOH 4:2:1): 0.56; [α]D20: ‒
15.0 (c: 0.25 in H2O); lit.
19 [α]D20: ‒ 13.5 (c: 1.00 in H2O); mp: 187 
°C; 1H-NMR (300 MHz, D2O): 0.70 (d, J = 5.8, 3H); 0.80 (d, J = 
5.8, 3H); 1.45‒1.55 (m, 3H); 1.95‒2.05 (m, 2H); 2.30‒2.40 (m, 
2H); 3.72 (dd, J = 6.2, 6.2, 1H); 4.20 (dd, J = 6.4, 6.4, 1H); 13C-
NMR (75 MHz, D2O): 20.7, 22.3, 24.6, 26.2, 31.3, 39.5, 51.9, 53.5, 
173.1, 174.7, 177.0; [M+H]+: 261.0. Anal. calcd for C11H20N2O5 
C, 50.76; H, 7.74; N, 10.76; found: C, 50.45; H, 7.60; N, 10.50. 
5.30 (S)-2-Amino-5-((R)-1-carboxy-3-methylbutylamino)-5-
oxopentanoic acid (5) 
Yield: 86%; Rf (n-butanol/H2O/AcOH 4:2:1): 0.56; [α]D20: + 
35.0 (c: 0.25 in H2O); mp: 100-102 °C; 
1H-NMR (300 MHz, D2O): 
0.70 (d, J = 6.2, 3H); 0.80 (d, J = 6.2, 3H); 1.45‒1.55 (m, 3H); 
1.95‒2.10 (m, 2H); 2.35 (ddd, J = 1.8, 8.8, 8.8, 2H); 3.80 (dd, J = 
6.4, 6.4, 1H); 4.22 (dd, J = 7.0, 7.0, 1H); 13C-NMR (75 MHz, 
D2O): 20.6, 22.3, 24.5, 25.9, 30.9, 39.4, 51.7, 53.0, 172.5, 174.5, 
176.9; [M+H]+: 261. Anal. calcd for C11H20N2O5 C, 50.76; H, 7.74; 
N, 10.76; found: C, 50.98; H, 7.90; N, 10.53. 
5.31 (S)-2-Amino-5-((S)-1-carboxy-2-hydroxyethylamino)-5-
oxopentanoic acid (6) 
Yield: 40%; Rf (n-butanol/H2O/AcOH 4:2:1): 0.24; mp: dec. T 
> 164 °C; [α]D20: + 11.6 (c: 0.35 in H2O); 1H-NMR (300 MHz, 
D2O): 2.00‒2.10 (m, 2H); 2.40 (ddd, J = 3.5, 6.2, 6.2, 2H); 3.70‒
3.85 (m, 3H); 4.38 (dd, J = 4.1, 4.1, 1H); 13C-NMR (75 MHz, 
D2O): 26.5, 31.9, 54.5, 57.3, 62.1, 174.3, 174.6, 176.4; [M+H]
+: 
235.0. [α]D20: ‒ 13 (c: 0.35 in H2O). Anal. calcd for C8H14N2O6 C, 
41.03; H, 6.03; N, 11.96; found: C, 41.30; H, 6.22; N, 11.78. 
5.32 (S)-2-Amino-5-((R)-1-carboxy-2-hydroxyethylamino)-5-
oxopentanoic acid (7) 
Yield: 40%; Rf (n-butanol/H2O/AcOH 4:2:1): 0.26; mp: dec. T 
> 156 °C; [α]D20: +12.3 (c: 0.40 in H2O); 1H-NMR (300 MHz, 
D2O): 2.00-2.10 (m, 2H); 2.40 (ddd, J = 3.5, 6.2, 6.2, 2H); 3.70-
3.85 (m, 3H); 4.38 (dd, J = 4.1, 4.1, 1H); 13C-NMR (75 MHz, 
D2O): 25.9, 31.0, 53.2, 55.1, 61.2, 172.9, 173.8, 174.6; [M+H]
+: 
235.0. [α]D20: ‒ 13 (c: 0.35 in H2O). Anal. calcd for C8H14N2O6 C, 
41.03; H, 6.03; N, 11.96; found: C, 41.28; H, 6.20; N, 11.80. 
5.33 (S)-2-((S)-4-Amino-4-carboxybutanamido)pentanedioic 
acid (8) 
Yield: 59%, Rf (n-butanol/H2O/AcOH 4:2:1): 0.29; [α]D20: ‒ 2.5 
(c: 0.50 in H2O); [α]D20: + 3.2 (c: 0.50 in 0.5 N HCl); lit.20 [α]D20: 
+ 3.4 (c: 1.00 in 0.5 N HCl); mp: 188-190 °C; 1H-NMR (300 MHz, 
D2O): 1.80‒1.95 (m, 1H); 2.00‒2.15 (m, 3H); 2.30‒2.45 (m, 4H); 
3.80 (dd, J = 6.3, 6.3, 1H); 4.25 (dd, J = 5.0, 9.1, 1H); 13C-NMR 
(75 MHz, D2O): 25.9, 26.0, 30.3, 31.3, 52.5, 53.5, 173.1, 174.7, 
175.5, 177.3; [M+H]+: 277.0. Anal. calcd for C10H16N2O7 C, 43.48; 
H, 5.84; N, 10.14; found: C, 43.70; H, 6.00; N, 9.98. 
5.34 (S)-2-((R)-4-Amino-4-carboxybutanamido)pentanedioic 
acid (9) 
Yield: 44%; Rf  (n-butanol/H2O/AcOH 4:2:1): 0.29; [α]D20: + 
15.2 (c: 0.25 in H2O); mp: 103-105 °C; 
1H-NMR (300 MHz, D2O): 
1.80‒1.95 (m, 1H); 2.00‒2.10 (m, 3H); 2.30‒2.40 (m, 4H); 3.80 
(dd, J = 6.3, 6.3, 1H); 4.25 (dd, J = 5.0, 9.1, 1H); 13C-NMR (75 
MHz, D2O): 25.9, 26.0, 30.2, 31.0, 52.4, 53.3, 172.9, 174.6, 175.5, 
177.3; [M+H]+: 277.0. Anal. calcd for C10H16N2O7 C, 43.48; H, 
5.84; N, 10.14; found: C, 43.75; H, 6.06; N, 9.90. 
5.35 (S)-6-Amino-2-((S)-4-amino-4-
carboxybutanamido)hexanoic acid (10) 
The residue was dissolved in a few drops of bidistilled water 
and purified on a column packed with Amberlite IR120. The resin 
was washed with bidistilled H2O until the pH was neutral and then 
the product was released from the resin with aqueous 1N NH3.The 
fractions containing the dipeptide were collected and lyophilized 
to give the desired product. 
Yield: 79%, Rf (n-butanol/H2O/AcOH 4:2:1): 0.14, [α]D20: + 4.0 
(c: 0.20 in H2O); lit.
21 [α]D20: + 3.5 (c: 1.00 in H2O); mp: dec. T > 
215°C; 1H-NMR (300 MHz, D2O): 1.25‒1.35 (m, 2H); 1.50‒1.60 
(m, 3H); 1.60‒1.70 (m, 1H); 1.95‒2.05 (m, 2H); 2.30‒2.40 (m, 
2H); 2.86 (ddd, J = 7.6, 7.6, 7.6, 2H); 3.62 (dd, J = 6.5, 6.5, 1H); 
4.00 (dd, J = 5.3, 8.5, 1H); 13C-NMR (75 MHz, D2O): 22.3, 26.5, 
26.5, 31.0, 31.9, 39.4, 54.4, 55.2, 174.2, 174.4, 179.2; [M+H]+: 
 7 
276.0. Anal. calcd for C11H21N3O5 C, 47.99; H, 7.69; N, 15.26; 
found: C, 47.70; H, 7.48; N, 15.46. 
5.36 (R)-6-Amino-2-((S)-4-amino-4-
carboxybutanamido)hexanoic acid (11) 
Yield: 65%; Rf (n-butanol/H2O/AcOH 4:2:1): 0.14; [α]D20: − 4.5 
(c: 0.35 in H2O); mp: dec. T > 205 °C; 
1H-NMR (300 MHz, D2O): 
1.20‒1.40 (m, 2H); 1.50‒1.60 (m, 2H); 1.60‒1.75 (m, 2H); 1.95‒
2.05 (m, 2H); 2.25‒2.35 (m, 2H); 2.86 (ddd, J = 7.3, 7.3, 7.3, 2H); 
3.66 (dd, J =5.9, 5.9, 1H); 4.02 (dd, J = 5.0, 8.2, 1H); 13C-NMR 
(75 MHz, D2O): 22.3, 26.4, 26.5, 31.0, 31.2, 39.4, 54.3, 55.2, 
174.2, 174.9, 179.2; [M+H]+: 276.0. Anal. calcd for C11H21N3O5 
C, 47.99; H, 7.69; N, 15.26; found: C, 47.75; H, 7.50; N, 15.50. 
5.37 (R)-2-Amino-5-(carboxymethylamino)-5-oxopentanoic 
acid (12) 
[α]D20: − 10.0 (c: 0.30 in H2O). Anal. calcd for C7H12N2O5 C, 
41.18; H, 5.92; N, 13.72; found: C, 40.98; H, 5.81; N, 13.93. 
5.38 (R)-2-Amino-5-((S)-1-carboxy-2-phenylethylamino)-5-
oxopentanoic acid (13) 
[α]D20: − 5.0 (c: 0.25 in H2O). Anal. calcd for C14H18N2O5 C, 
57.13; H, 6.16; N, 9.52; found: C, 57.38; H, 6.30; N, 9.40. 
5.39 (R)-2-Amino-5-((R)-1-carboxy-2-phenylethylamino)-5-
oxopentanoic acid (14) 
[α]D20: − 17.1 (c: 0.30 in H2O). Anal. calcd for C14H18N2O5 C, 
57.13; H, 6.16; N, 9.52; found: C, 57.30; H, 6.00; N, 9.80. 
5.40 (R)-2-Amino-5-((S)-1-carboxy-3-methylbutylamino)-5-
oxopentanoic acid (15) 
[α]D20: ‒ 33.0 (c: 0.25 in H2O). Anal. calcd for C11H20N2O5 C, 
50.76; H, 7.74; N, 10.76; found: C, 50.93; H, 7.90; N, 10.50. 
5.41 (R)-2-Amino-5-((R)-1-carboxy-3-methylbutylamino)-5-
oxopentanoic acid (16) 
[α]D20: + 15.6 (c: 0.25 in H2O). Anal. calcd for C11H20N2O5 C, 
50.76; H, 7.74; N, 10.76; found: C, 50.50; H, 7.58; N, 10.87. 
5.42 (R)-2-Amino-5-((S)-1-carboxy-2-hydroxyethylamino)-5-
oxopentanoic acid (17) 
[α]D20: ‒ 12.3 (c: 0.40 in H2O). Anal. calcd for C8H14N2O6 C, 
41.03; H, 6.03; N, 11.96; found: C, 40.80; H, 5.80; N, 12.10. 
5.43 (R)-2-Amino-5-((R)-1-carboxy-2-hydroxyethylamino)-5-
oxopentanoic acid (18) 
[α]D20: ‒ 13.0 (c: 0.35 in H2O). Anal. calcd for C8H14N2O6 C, 
41.03; H, 6.03; N, 11.96; found: C, 40.85; H, 5.82; N, 12.16. 
5.44 (R)-2-((S)-4-Amino-4-carboxybutanamido)pentanedioic 
acid (19) 
[α]D20: ‒ 16.0 (c: 0.25 in H2O). Anal. calcd for C10H16N2O7 C, 
43.48; H, 5.84; N, 10.14; found: C, 43.69; H, 5.98; N, 9.97. 
5.45 (R)-2-((R)-4-amino-4-carboxybutanamido)pentanedioic 
acid (20) 
[α]D20: + 3.0 (c: 0.50 in H2O). Anal. calcd for C10H16N2O7 C, 
43.48; H, 5.84; N, 10.14; found: C, 43.80; H, 6.00; N, 9.93. 
5.46 (S)-6-Amino-2-((R)-4-amino-4-
carboxybutanamido)hexanoic acid (21) 
The residue was dissolved in a few drops of bidistilled water 
and purified on a column packed with Amberlite IR120. The resin 
was washed with bidistilled H2O until the pH was neutral and then 
the product was released from the resin with aqueous 1 N NH3.The 
fractions containing the dipeptide were collected and lyophilized 
to give the desired product.  
[α]D20: + 4.0 (c: 0.35 in H2O). Anal. calcd for C11H21N3O5 C, 
47.99; H, 7.69; N, 15.26; found: C, 48.23; H, 7.90; N, 15.00. 
5.47 (R)-6-Amino-2-((R)-4-amino-4-
carboxybutanamido)hexanoic acid (22) 
[α]D20: − 4.0 (c: 0.20 in H2O). Anal. calcd for C11H21N3O5 C, 
47.99; H, 7.69; N, 15.26; found: C, 48.18; H, 7.93; N, 14.98. 
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